The Challenge of Misdiagnosed NSAID Allergies

Nonsteroidal anti-inflammatory drugs (NSAIDs) remain the most common triggers for drug hypersensitivity reactions worldwide. Despite this, clinicians rule out the diagnosis in approximately 60% of patients who present with suggestive symptoms. This discrepancy creates a significant healthcare burden. Mislabeled patients unnecessarily avoid essential medications, which increases diagnostic delays and healthcare costs. Improving the NSAID hypersensitivity diagnosis is therefore critical for optimizing patient care and resource allocation.

Researchers recently addressed this gap by developing and validating a machine learning (ML) model. They recruited both retrospective and prospective populations from the Allergy Unit of Malaga Regional University Hospital in Spain. By comparing one logistic regression analysis with six ML-based models, the team identified the most efficient tool for clinical application. The study specifically focused on individuals with suspected NSAID-induced hypersensitivity reactions (HSRs) whose diagnoses were already confirmed through standard protocols.

Optimizing NSAID Hypersensitivity Diagnosis with LGBM

The study found that the Light Gradient-Boosting Machine (LGBM) model outperformed all other approaches. In the retrospective analysis, the LGBM model demonstrated a remarkable 99% sensitivity and 97% accuracy. Furthermore, the model maintained high performance during external validation across different clinical centers in Madrid, Barcelona, and Salamanca. Specifically, the final validated LGBM model achieved an accuracy of 91.76% and an area under the curve (AUC) of 95.19%.

Consequently, this advanced computational model offers a reliable way to differentiate between truly hypersensitive patients and those who can safely receive NSAIDs. Because the model provides a high degree of certainty, it can be easily integrated into routine clinical settings. Therefore, clinicians can use this technology to reduce waiting lists and prevent the unnecessary avoidance of effective pain management therapies. This is particularly relevant in busy clinical environments where rapid and accurate screening is essential.

Frequently Asked Questions

How accurate is the machine learning model for NSAID hypersensitivity?

The Light Gradient-Boosting Machine (LGBM) model achieved a sensitivity of 99% and an accuracy of 97% in initial tests. Even during external validation across multiple clinical sites, it maintained an accuracy of approximately 95%.

Why is it important to improve the diagnosis of NSAID allergies?

Approximately 60% of suspected cases are eventually ruled out. Improving the accuracy of the initial diagnosis prevents patients from unnecessarily avoiding effective medications and reduces the burden on allergy specialist waiting lists.

Can this ML model be used in standard clinical practice?

Yes, the researchers designed the LGBM model to be easily incorporated into clinical settings. It serves as an efficient tool to help clinicians differentiate between truly hypersensitive individuals and those who do not require drug avoidance.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Sáenz de Santa María R et al. Machine Learning Model Development and Validation in Individuals With Suggestive Hypersensitivity to Nonsteroidal Anti-inflammatory Drugs. J Investig Allergol Clin Immunol. 2026 Feb 09. doi: 10.18176/jiaci.1159. PMID: 41661666.


2. Doña I, et al. An algorithm for the diagnosis and treatment of nonsteroidal antiinflammatory drugs hypersensitivity, 2024 update. Allergy. 2025;80(4):1183-1186.


3. Kushnir IV, et al. Predictive models and applicability of artificial intelligence-based approaches in drug allergy. Curr Opin Allergy Clin Immunol. 2024;24(4):231-237.